Trial reportBreast cancer research and treatment2015
Expression profiling of circulating tumor cells in metastatic breast cancer.
Trial report in Breast cancer research and treatment, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility.International journal of molecular sciences · 2017Pooled it
- Article
- Combination of furosemide, gold, and dopamine as a potential therapy for breast cancer.Functional & integrative genomics · 2023Article
- Clinical Relevancy of Circulating Tumor Cells in Breast Cancer: Epithelial or Mesenchymal Characteristics, Single Cells or Clusters?International journal of molecular sciences · 2022Review
- Circulating tumour cells in the -omics era: how far are we from achieving the 'singularity'?British journal of cancer · 2022Review
- Identification of Key Genes and Pathways Involved in Circulating Tumor Cells in Colorectal Cancer.Analytical cellular pathology (Amsterdam) · 2022Article
- Mitochondria dysfunction in circulating tumor cells.Frontiers in oncology · 2022Review
- miR-205-5p Downregulation andInternational journal of molecular sciences · 2021Article
- Review
- Understanding breast cancer heterogeneity through non-genetic heterogeneity.Breast cancer (Tokyo, Japan) · 2021Review
- RNA-Based CTC Analysis Provides Prognostic Information in Metastatic Breast Cancer.Diagnostics (Basel, Switzerland) · 2021Article
- Cellular Mechanisms of Circulating Tumor Cells During Breast Cancer Metastasis.International journal of molecular sciences · 2020Review
- Article
- Circulating tumor cells in hepatocellular carcinoma: single-cell based analysis, preclinical models, and clinical applications.Theranostics · 2020Review
- The current status of the clinical utility of liquid biopsies in cancer.Expert review of molecular diagnostics · 2019Review
- A Novel Panel of 80 RNA Biomarkers with Differential Expression in Multiple Human Solid Tumors against Healthy Blood Samples.International journal of molecular sciences · 2019Article
- Genomics applied to the treatment of breast cancer.Oncotarget · 2019Review
- Profiling of Invasive Breast Carcinoma Circulating Tumour Cells-Are We Ready for the 'Liquid' Revolution?Cancers · 2019Review
- Testing for differentially expressed genetic pathways with single-subject N-of-1 data in the presence of inter-gene correlation.Statistical methods in medical research · 2018Article
- Disseminated tumour cells in bone marrow are the source of cancer relapse after therapy.Journal of cellular and molecular medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Circulating tumor cells (CTCs) are prognostic in all stages of breast cancer. However, since they are extremely rare, little is known about the molecular nature of these cells. We report a novel strategy for the isolation and expression profiling of pure populations of CTCs derived from peripheral blood. We developed a method to isolate CTCs based on immunomagnetic capture followed by fluorescence-activated cell sorting (IE/FACS). After assay validation using the BT474 cell line spiked into blood samples in vitro, RNA from CTCs isolated from the blood of five metastatic breast cancer (MBC) patients was linearly amplified and subjected to gene expression profiling via cDNA microarrays. We isolated a range of 9-993 captured CTCs from five MBC patients' blood and profiled their RNA in comparison to a diverse panel of primary breast tumors (n = 55). Unsupervised hierarchical clustering revealed that CTC profiles clustered with more aggressive subtypes of primary breast tumors and were readily distinguishable from peripheral blood (PB) and normal epithelium. Differential expression analysis revealed CTCs to have downregulated apoptosis, and they were distinguishable from PB by the relative absence of immune-related signals. As expected, CTCs from MBC had significantly higher risk of recurrence scores than primary tumors (p = 0.0073). This study demonstrates that it is feasible to isolate CTCs from PB with high purity through IE/FACS and profile them via gene expression analysis. Our approach may inform the discovery of therapeutic predictors and be useful for real-time identification of emerging resistance mechanisms in MBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.